Stockreport

TCR² Therapeutics Announces Pipeline Priorities for 2023

TCR2 Therapeutics Inc.  (TCRR) 
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am Check Earnings Report
PDF gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation enhanced programs TC-510 [Read more]